Navigation

POS

Perfect the Biochemistry Behind ADC Synthesis, Vaccine and Nanoparticle Conjugation

Registration

Online Registration is Open!
Register by Friday, March 18 to Save Up to $400!
»Pricing Chart

Add to Outlook Calendar

Find Another IBC Event

Transitioning Innovation into Viable Therapeutic Candidates

June 13-15, 2016
Parc 55 Hilton
San Francisco, CA

Alt language

Alternative Language Options:

  • Japanese
  • Korean
  • Taiwanese
  • Chinese

Event Overview

Event Overview

 

Where the drug discovery community gathers to:

  • Develop Platforms to Support Novel Linkers and Payloads
    • Explore how the new class of DNA-alkylating agents are designed and synthesized
    • Mitigate toxicity risks and ensure proper potency with the latest data from Genentech and Immunogen
  • Help define CMC standards
    • Combat analytical and characterization challenges with new data from MedImmune
    • Learn how Pfizer creates characterization roadmaps to evaluate molecular complexity and critical quality attributes
  • Understand conjugate advances beyond ADCs
    • Hear the latest data on bispecific, nano-particle, and vaccine conjugation
    • Eliminate heterogeneity and increase the therapeutic window with new data from GSK and Pfizer

View the Agenda

Turn your research into viable therapeutic candidates with

  • Annaliesa S. Anderson, Ph.D. photo Annaliesa Anderson, Ph.D. VP & CSO Bacterial Vaccines, VRD, Pfizer, Inc.
  • Dimiter Dimitrov, Ph.D. photo Dimiter Dimitrov, Ph.D. Senior Investigator, Protein Interactions, National Cancer Institute, NIH
  • Greg Adams, Ph.D. photo Greg Adams, Ph.D. Chief Development Officer, Viventia Biotechnologies Inc
  • Thomas Pillow, Ph.D. photo Thomas Pillow, Ph.D. Scientist, ADC Team Leader, Genentech

Join the industry's leading Conjugation Conference

  • 100+ Attendees
  • 20+ New Data sessions
  • 10+ Hours of Dedicated Networking

Networking Opportunities

Sponsors and Exhibitors

Position yourself as a thought leader and showcase your innovations to an engaged community of scientists and researchers. Contact Patricia Rose at prose@ibcusa.com to receive the sponsor prospectus and to discuss custom packages.

Showcase at the Event

Unite discovery, research and development

  • Access 80+ New Data And Case Study Presentations
    Bioconjugates: From Targets to Therapeutics is co-located with Next Generation Protein Therapeutics and Cell Line Development & Engineering resulting in a unique collaborative experience where experts share insights and inspiring data.
  • All-Access Pass Upgrade
    When you upgrade to the all-access pass you gain the opportunity to collaborate with the entire drug discovery and development ecosystem. Connect with process development and other protein engineers to ensure therapeutic success.
  • A Team Experience
    With so much content and 400+ attendees to meet with packed, you'd need to bring your team to cover it all. Group discounts are available.

Co-Located Events

Patterns

Footer

Javascript